Clinical Report: Combination Immunotherapy Approaches in Metastatic RCC

Overview

This meta-analysis evaluates the efficacy of combination immunotherapy in patients with favorable risk scores in metastatic renal cell carcinoma (mRCC). Findings indicate that while combination therapies improve progression-free survival, they do not significantly enhance overall survival compared to sunitinib monotherapy.

Background

Renal cell carcinoma (RCC) is a prevalent malignancy with a significant proportion of patients presenting with metastatic disease. Recent advancements in treatment, particularly the introduction of immunotherapy and targeted therapies, have transformed the management of mRCC. Understanding the optimal treatment strategies for patients with favorable risk scores is crucial for improving patient outcomes.

Data Highlights

This study included data from five phase 3 randomized clinical trials focusing on first-line treatment for advanced RCC, specifically targeting patients with favorable IMDC scores.

Key Findings

• Combination therapies involving immune-checkpoint inhibitors (ICIs) and anti-VEGF TKIs show improved progression-free survival (PFS) in favorable risk patients.
• There is no statistically significant improvement in overall survival (OS) for favorable risk patients receiving combination therapies compared to sunitinib.
• Patients with intermediate and poor risk benefit more from combination therapies in terms of OS and objective response rates (ORR).
• Predictive factors for selecting optimal ICI-TKI combinations in favorable risk patients remain inadequately defined.
• Monotherapy with TKIs is still a viable option for favorable risk patients due to the lack of clear superiority of combination therapies in this subgroup.

Clinical Implications

Clinicians should consider the lack of OS benefit when prescribing combination immunotherapy for patients with favorable risk scores in mRCC. TKI monotherapy remains a valid treatment option and should be discussed with patients as part of a shared decision-making process.

Conclusion

The findings underscore the need for further research to identify predictive factors that could guide treatment decisions for favorable risk patients in metastatic RCC. Current evidence suggests that while combination therapies enhance PFS, they do not confer a significant OS advantage over traditional TKI therapies.

References

1. Author(s)/Org, Source, Year -- Title
2. Bristol Myers Squibb, News Release, 2024 -- Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab)
3. Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma, JAMA Network, 2023 -- Article Abstract
4. Immunotherapy combinations in favourable risk score metastatic renal cell carcinoma, PMC, 2023 -- Article
5. The ASCO Post — A Conversation With Arie Belldegrun, MD, FACS, and Allan Pantuck, MD, MS, FACS
6. The ASCO Post — Expert Point of View: Adjuvant Immunotherapy Provides No Clinical Benefit in Patients with High‑risk Renal Cell Carcinoma
7. The ASCO Post — Nivolumab Plus Ipilimumab vs Sunitinib Alone as First-Line Therapy for Metastatic Renal Cell Carcinoma
8. The ASCO Post — Combination Immunotherapy Benefits Subset of Patients With Advanced Prostate Cancer
9. NCCN Kidney Cancer Guidelines
10. ESMO Clinical Practice Guideline for Renal Cell Carcinoma
11. EAU Guidelines on Renal Cell Carcinoma
12. Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial | Nature Medicine
13. Bristol Myers Squibb - Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
14. Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma | Cancer Biomarkers | JAMA Network Open | JAMA Network
15. Immunotherapy combinations in favourable risk score metastatic renal cell carcinoma, an individual patients data metanalysis - PMC